Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Kidney Case Conference: How I Treat
You have accessRestricted Access

Electrolyte Disorders in Kidney Transplantation

Clifford D. Miles and Scott Gregory Westphal
CJASN March 2020, 15 (3) 412-414; DOI: https://doi.org/10.2215/CJN.09470819
Clifford D. Miles
Division of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Gregory Westphal
Division of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Scott Gregory Westphal
  • Article
  • Info & Metrics
  • View PDF
Loading
  • kidney transplantation
  • electrolytes
  • hyperparathyroidism
  • hyperkalemia
  • hypomagnesemia
  • immunosuppression
  • acid-base imbalance
  • water-electrolyte balance

Introduction

Kidney transplantation is the treatment of choice for ESKD. However, transplantation is associated with a variety of potential complications. Although much of the focus surrounds immunosuppression, electrolyte imbalances frequently arise. Herein, we discuss several common issues: hyperkalemia, hypomagnesemia, and hyperparathyroidism, with the emphasis on management.

Hyperkalemia

Elevation in serum potassium is common after kidney transplantation, reported in 25%–44% of patients (1). Contributory factors include acute or chronic reduction in GFR, metabolic acidosis, and medications, including trimethoprim, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and calcineurin inhibitors. The latter (tacrolimus and cyclosporine) are noteworthy, as their contribution to hyperkalemia can be significant, and stopping them requires a new immunosuppressive regimen. Mechanisms by which calcineurin inhibitors affect potassium include inhibition of mineralocorticoid production, mineralocorticoid resistance, and activation of the thiazide-sensitive sodium-chloride cotransporter in the distal convoluted tubule (1).

Although hyperkalemia can present with weakness or cardiac conduction disturbance, it is most often detected on routine laboratory monitoring. For relatively mild elevation of serum potassium (5.1–5.7 mEq/L), we begin by assessing the complete metabolic profile, immunosuppressant level, and clinical picture, as well as minimizing dietary potassium. If new allograft dysfunction is present, hyperkalemia may be related, and management should be directed toward diagnosing and treating the cause of kidney injury. With stable graft function, metabolic acidosis (usually nonanion gap in this setting) can be addressed by supplemental oral sodium bicarbonate, with goal serum bicarbonate of >22 mEq/L. Although the correction of metabolic acidosis may only marginally improve potassium levels, there may be long-term benefit in slowing of CKD progression. As calcineurin inhibitor effects on serum potassium tend to be level-related, the dose should be adjusted to achieve the minimum acceptable concentration. Loop diuretics may be useful in promoting kaliuresis, although we reserve use of these agents for patients with evidence of volume overload (edema, short-term weight gain). Experimental evidence suggests that patients with a phenotype of hyperkalemia, hypertension, and acidosis (consistent with sodium-chloride cotransporter activation) may benefit from treatment with thiazides (2).

In refractory hyperkalemia, potassium binding agents are often effective. The recently approved agents patiromer and sodium zirconium cyclosilicate may offer advantages over the older sodium polystyrene sulfonate. Although large-scale clinical studies have not been performed in transplant recipients, we have used patiromer in patients with persistent hyperkalemia and have seen positive results. This aligns with a recent publication showing safety and efficacy in 19 transplant patients managed with patiromer (3). We instruct patients to take patiromer 4 hours after their morning mycophenolate, and have not witnessed issues with drug–drug interaction.

More extreme hyperkalemia may warrant evaluation in the emergency department. This allows for electrocardiographic monitoring, careful volume assessment, and the administration of transient membrane stabilization with intravenous calcium and potassium-shifting therapy with insulin/dextrose. In our experience, acute dialysis is seldom required, particularly if allograft function is preserved.

Hypomagnesemia

Hypomagnesemia is very common early after transplantation, and persists in at least 20% of recipients (4). Post-transplant hypomagnesemia may be caused by both gastrointestinal and urinary magnesium losses. Factors contributing to gastrointestinal losses include diarrhea and medications, including proton pump inhibitors and patiromer. Urinary losses may be exacerbated by the use of loop or thiazide diuretics, and by calcineurin inhibitors, which induce urinary magnesium wasting via downregulation of EGF and the distal magnesium transient receptor potential melastatin 6 (5). Although hypomagnesemia can cause confusion, weakness, and neuromuscular irritability, it is usually asymptomatic, noted on routine laboratory tests. However, hypomagnesemia may be associated with glucose dysregulation, endothelial dysfunction, and cardiovascular events, underscoring its potential importance in long-term outcomes (6).

Unfortunately, hypomagnesemia tends to be difficult to correct. Our algorithm starts with dietary modification and oral supplementation with magnesium oxide. Some patients require titration up to 800 mg twice daily, although diarrhea is a frequent dose-limiting side effect. Magnesium chloride is another oral preparation that may be better tolerated, although neither in our experience will reliably increase serum magnesium into the normal range. As with hyperkalemia, it is prudent to ensure immunosuppressant levels are appropriate. The need for loop or thiazide diuretics and proton pump inhibitors should be reviewed, and alternatives considered if appropriate, although thiazide-induced magnesium wasting may be blunted in patients on calcineurin inhibitors (2). We have had success used amiloride, the potassium (and magnesium)-sparing diuretic. It tends to be well tolerated, and we usually administer it while continuing magnesium supplementation. Clearly, one needs to be cognizant of the effect on potassium levels.

Post-Transplant Hyperparathyroidism

Disorders in bone-mineral metabolism, including hyperparathyroidism, are common in patients with ESKD. After transplantation, restoration of kidney function generally corrects the stimuli for hyperparathyroidism, including hyperphosphatemia and hypovitaminosis D, resulting in the return of autoregulation of parathyroid hormone (PTH) secretion. However, parathyroid regression is frequently incomplete, resulting in persistent post-transplant hyperparathyroidism. The functional allograft responds to elevated PTH and fibroblast growth factor-23 (FGF-23) with hyperphosphaturia, resulting in hypophosphatemia. Likewise, post-transplant hypercalcemia develops in response to persistently elevated PTH, reduced skeletal resistance to PTH, and increasing active vitamin D levels.

Hypercalcemia and hypophosphatemia develop in approximately 50% of transplant recipients, often most pronounced 2–8 weeks after transplantation (7). Although FGF-23 levels fall quickly, hyperparathyroidism frequently persists, with >85% of recipients having elevated PTH levels 1 year after transplantation. Persistent post-transplant hyperparathyroidism is associated with an increased risk of acute kidney allograft injury, graft loss, fractures, and mortality (8).

When hypercalcemia develops, medications that increase serum calcium should be discontinued, including vitamin D analogs, calcium supplements, calcium-based phosphate binders, and thiazide diuretics. Patients should maintain adequate solute and water intake to avoid volume depletion, which can exacerbate hypercalcemia through increased kidney absorption. Post-transplant hypercalcemia is often mild and self-limited; however, when hypercalcemia is severe or prolonged, additional interventions may be warranted.

Before calcimimetics, parathyroidectomy was often the only therapy to provide a durable response to hypercalcemia caused by post-transplant hyperparathyroidism. However, with the availability of cinacalcet, this alternative to surgical parathyroidectomy is now widely utilized. In a recent randomized trial, parathyroidectomy was compared with cinacalcet for the treatment of post-transplant hyperparathyroidism (9). All patients treated with parathyroidectomy achieved normocalcemia versus 67% of those treated with cinacalcet, and the PTH reduction was greater in the surgical group. Parathyroidectomy was associated with an improvement in femoral neck bone mineral density with no improvement observed in the cinacalcet group. An economic analysis estimated that the cost of parathyroidectomy was equivalent to 14 months of cinacalcet.

There are, however, reasons to avoid surgery, including patient choice, specific surgical risk factors, and the desire to avoid early short-term risk from the transplant program’s standpoint. For such reasons, calcimimetics are being used with increasing frequency, especially in the early post-transplant period, to avoid or delay parathyroidectomy. In a randomized, controlled trial in patients with hypercalcemia attributed to post-transplant hyperparathyroidism, 79% of patients treated with cinacalcet achieved normocalcemia compared with just 4% given placebo (10). PTH in cinacalcet-treated patients dropped significantly and phosphorus normalized, whereas there was minimal change in the placebo group. However, treatment with cinacalcet did not improve clinical outcomes such as bone density, allograft function, or allograft/patient survival. Further, after cinacalcet discontinuation, calcium returned toward pretreatment levels, as did phosphorus and PTH, suggesting that cinacalcet did not facilitate involution of parathyroid hyperplasia.

At our center, we attempt to avoid parathyroidectomy when possible, particularly within the first post-transplant year, as some patients will develop at least partial resolution of hypercalcemia. We initiate cinacalcet in patients with moderate hypercalcemia (>11.0 mg/dl), particularly if graft dysfunction or symptoms are present. We start cinacalcet at 30 mg daily, and titrate as tolerated to achieve normocalcemia. Gastrointestinal side effects and cost can be barriers to use and dose escalation. We subsequently attempt to wean cinacalcet after the first transplant year. If hypercalcemia redevelops as cinacalcet is weaned, we discuss the risks and benefits of parathyroidectomy compared with remaining on cinacalcet indefinitely. We consider earlier parathyroidectomy in patients with refractory hypercalcemia that cannot be managed with cinacalcet because of cost, side effects, or ineffectiveness.

Although cinacalcet often raises serum phosphate, maintaining normal phosphate levels can be challenging in the early post-transplant period, particularly in those with good allograft function. Fortunately, significant symptoms rarely develop until phosphorus is <1.0 mg/dl. Mild hypophosphatemia can often be managed through increased dietary intake (e.g., dairy products). When phosphorus levels drop below 1.8 mg/dl, we initiate oral neutral phosphorus salt supplementation. We generally do not titrate the dose above 500 mg two times per day even if phosphorus levels remain low, as excessive supplementation can stimulate PTH and FGF-23, enhancing phosphaturia.

Summary

Disturbances of potassium, magnesium, and calcium/phosphorus are common after kidney transplantation, and deserve careful management. Serial laboratory assessment of these electrolytes is central to titration of supplements and other interventions. As a word of caution, the steps we have described here may lead to significant increase in pill burden, as these disorders often coexist. The potential effect on quality of life and adherence to immunosuppressive medications should be borne in mind.

Disclosures

Dr. Miles and Dr. Westphal have nothing to disclose.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Pochineni V,
    2. Rondon-Berrios H
    : Electrolyte and acid-base disorders in the renal transplant recipient. Front Med (Lausanne) 5: 261, 2018pmid:30333977
    OpenUrlPubMed
  2. ↵
    1. Hoorn EJ,
    2. Walsh SB,
    3. McCormick JA,
    4. Fürstenberg A,
    5. Yang CL,
    6. Roeschel T,
    7. Paliege A,
    8. Howie AJ,
    9. Conley J,
    10. Bachmann S,
    11. Unwin RJ,
    12. Ellison DH
    : The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med 17: 1304–1309, 2011pmid:21963515
    OpenUrlCrossRefPubMed
  3. ↵
    1. Lim MA,
    2. Sawinski D,
    3. Trofe-Clark J
    : Safety, effectiveness, and tolerability of patiromer in kidney transplant recipients. Transplantation 103: e281–e282, 2019
    OpenUrl
  4. ↵
    1. De Waele L,
    2. Van Gaal PJ,
    3. Abramowicz D
    : Electrolytes disturbances after kidney transplantation. Acta Clin Belg 74: 48–52, 2019pmid:30482110
    OpenUrlPubMed
  5. ↵
    1. Van Laecke S,
    2. Van Biesen W
    : Hypomagnesaemia in kidney transplantation. Transplant Rev (Orlando) 29: 154–160, 2015pmid:26001746
    OpenUrlPubMed
  6. ↵
    1. Sinangil A,
    2. Celik V,
    3. Barlas S,
    4. Sakaci T,
    5. Koc Y,
    6. Basturk T,
    7. Akin EB,
    8. Ecder T
    : New-onset diabetes after kidney transplantation and pretransplant hypomagnesemia. Prog Transplant 26: 55–61, 2016pmid:27136250
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wolf M,
    2. Weir MR,
    3. Kopyt N,
    4. Mannon RB,
    5. Von Visger J,
    6. Deng H,
    7. Yue S,
    8. Vincenti F
    : A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation 100: 184–193, 2016pmid:26177089
    OpenUrlCrossRefPubMed
  8. ↵
    1. Pihlstrøm H,
    2. Dahle DO,
    3. Mjøen G,
    4. Pilz S,
    5. März W,
    6. Abedini S,
    7. Holme I,
    8. Fellström B,
    9. Jardine AG,
    10. Holdaas H
    : Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 99: 351–359, 2015pmid:25594550
    OpenUrlCrossRefPubMed
  9. ↵
    1. Evenepoel P,
    2. Cooper K,
    3. Holdaas H,
    4. Messa P,
    5. Mourad G,
    6. Olgaard K,
    7. Rutkowski B,
    8. Schaefer H,
    9. Deng H,
    10. Torregrosa JV,
    11. Wuthrich RP,
    12. Yue S
    : A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant 14: 2545–2555, 2014pmid:25225081
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cruzado JM,
    2. Moreno P,
    3. Torregrosa JV,
    4. Taco O,
    5. Mast R,
    6. Gómez-Vaquero C,
    7. Polo C,
    8. Revuelta I,
    9. Francos J,
    10. Torras J,
    11. García-Barrasa A,
    12. Bestard O,
    13. Grinyó JM
    : A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol 27: 2487–2494, 2016pmid:26647424
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (3)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 3
March 06, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Electrolyte Disorders in Kidney Transplantation
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Electrolyte Disorders in Kidney Transplantation
Clifford D. Miles, Scott Gregory Westphal
CJASN Mar 2020, 15 (3) 412-414; DOI: 10.2215/CJN.09470819

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Electrolyte Disorders in Kidney Transplantation
Clifford D. Miles, Scott Gregory Westphal
CJASN Mar 2020, 15 (3) 412-414; DOI: 10.2215/CJN.09470819
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Introduction
    • Hyperkalemia
    • Hypomagnesemia
    • Post-Transplant Hyperparathyroidism
    • Summary
    • Disclosures
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Resistant Hypertension in CKD
  • Walkaway PIRRT (as SLED) for Acute Kidney Injury
  • How We Manage Hypertension in a Patient with a Recent Stroke
Show more Kidney Case Conference: How I Treat

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Keywords

  • kidney transplantation
  • electrolytes
  • hyperparathyroidism
  • Hyperkalemia
  • hypomagnesemia
  • immunosuppression
  • Acid-Base Imbalance
  • water-electrolyte balance

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire